Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin to Enhance Prolonged Exposure Therapy for PTSD
NCT04228289Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2021
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in post-traumatic stress disorder (PTSD) (2 arms), sponsored by VA Office of Research & Development. Primary endpoints: Change in Post Traumatic Stress Disorder Symptom Severity - Clinician Rated at 10 weeks and Change in Post Traumatic Stress Disorder Symptom Severity - Self Report at 10 weeks. Started Jan 2021; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04228289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228289.